In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.
In patients at high-bleeding risk (HBR) implanted with a drug-eluting coronary stent, 1 month of dual antiplatelet therapy (DAPT) is as good as 3 months or longer – with significantly less bleeding – in the MASTER DAPT* trial, that experts said shorter DAPT post coronary stenting may be the strategy moving forward.
The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Under 130 mm Hg – that’s how low clinicians can go in terms of systolic blood pressure (SBP) to reduce cardiovascular events in older, hypertensive Chinese patients, suggests the multicentre STEP* trial.
Swapping regular salt for a reduced-sodium salt substitute may cut stroke, major adverse cardiovascular event (MACE)*, and death rates in individuals with a risk of stroke, according to results of the SSaSS** trial.
A quadruple combination containing quarter doses of four blood pressure (BP)-lowering drugs in a single pill — termed a quadpill — led to better BP control than using monotherapy for initial treatment of hypertension, according to the QUARTET study presented at ESC 2021.
Receiving an influenza vaccination after hospitalization for an invasive coronary procedure or a myocardial infarction (MI) may reduce the risk of all-cause or cardiovascular (CV) death, according to results of the IAMI* trial.
Alcohol consumption during late adolescence and early adulthood was associated with increased arterial stiffness, which may lead to future cardiovascular events, according to a study presented at ESC 2021.
Regular intake of saturated fatty acids (SFA) from meat could increase cardiovascular disease (CVD) risk whereas dairy sources, grains, fruits, and vegetables could be cardio-protective, suggests a study in the UK.
Empagliflozin significantly reduces the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) vs placebo in patients with heart failure with preserved ejection fraction (HFpEF) with or without diabetes, according to results of the EMPEROR-Preserved trial presented at the European Society of Cardiology (ESC) Congress 2021.